DXCM INVESTOR ALERT: DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
September 15, 2024) - The law firm of Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of DexCom, Inc. (NASDAQ: DXCM) securities between January 8, 2024 and July 25, 2024, inclusive ...
Yahoo Finance11d
3 Reasons DexCom Looks Like a No-Brainer Buy Right Now
Investors have also been growing concerned about its prospects, especially if weight loss drugs can lead to a reduction in diabetes cases in the long run. Down more than 40% this year, DexCom's ...
DXCM STOCK DEADLINE: If You Suffered Losses on Your DexCom, Inc. Investment, Notify BFA Law Before Approaching October 21 Class Action Deadline
New York, New York-- (Newsfile Corp. - September 14, 2024) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and ...
Stockhouse11d
DXCM INVESTOR NOTICE: If You Invested in DexCom, Inc., Contact BFA Law Before Imminent October 21 Deadline in Securities Fraud Class Action Case
NEW YORK, NY / ACCESSWIRE / September 12, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ:DXCM) and certain of the ...
Stockhouse11d
Stockholders Can Contact The Schall Law Firm About A Case Against DexCom, Inc. For Securities Law Violations
When the market learned the truth about DexCom, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in ...
Yahoo Finance3d
DexCom, Inc. (DXCM)
Higgins cites the growing use cases for GLP-1s, particularly in the treatment of pre-diabetic patients, as a forceful headwind to DexCom. Its glucose monitoring devices are only designed for a ...
FierceBiotech28d
Dexcom's Stelo, its first over-the-counter glucose monitor, hits the market
After getting the green light from the FDA back in March, Dexcom today launched its first over-the-counter wearable continuous glucose biosensor, Stelo, in the U.S. market. The device is now ...
San Diego Union-Tribune23d
Dexcom starts selling its new over-the-counter glucose monitor. Here’s how much it costs
San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing ...
Nasdaq21d
Is DexCom a Millionaire-Maker Stock?
Medical device specialist DexCom (NASDAQ: DXCM) is going through a rough patch. The company's shares dropped off a cliff following its second-quarter earnings report. However, zooming out helps ...
Reuters28d
Dexcom launches over-the-counter continuous glucose sensors in the US
Aug 26 (Reuters) - Dexcom (DXCM.O), opens new tab said on Monday its over-the-counter continuous glucose monitor, Stelo, is now available for use in the United States at a price of up to $99.
Morningstar28d
Stelo by Dexcom, the First Over-the-Counter Glucose Biosensor in the U.S., Is Now Available
Stelo is a small biosensor worn on the back of the upper arm that leverages Dexcom’s most accurate glucose sensing technology.5 It is specifically designed to provide the 125 million Americans6 ...